Who is eligible for clinical trial NCT06554288?

Participants must meet the protocol's inclusion criteria for Pediatric Disorder. The stated age range is 5 Years to 17 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06554288 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-19

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy (NCT06554288)

Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Children's Mercy Hospital Kansas City

🩺 Plain-English Summary (8th-Grade Level)

This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (4 items).

Location: Children's Mercy Hospital Kansas City — Kansas City, Missouri

Age range: 5 Years to 17 Years

🧪 Interventions in This Study

Trihexyphenidyl (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Ages 5-17 years of age
Diagnosis of cerebral palsy and dystonia causing interference
Parent/legal guardian of a child with a diagnosis of cerebral palsy and dystonia
Parent/legal guardian is willing and able to provide informed permission/assent for the study

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Previously or currently taking trihexyphenidyl
Patients turning 18 years of age within the study period (16 weeks from Study Day 1)
A language barrier for the patient that precludes communication and/or the ability to complete study-related requirements

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Children's Mercy Hospital Kansas City — Kansas City, Missouri

📞 Contact the Study Coordinator

Phone: (816) 302-3331

Email: rngelineaumorel@cmh.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Pediatric Disorder

Comparing the Difference in Pain Control in the Pediatric General Surgery Population: to Alternate or Combine Acetaminophen and Ibuprofen? — Temple, Texas
New Ways of Doing Magnetic Resonance Imaging in Children and Adults — New York, New York

Explore by condition: All Pediatric Disorder clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗